Steve Tokarz
CEO
Peptinovo Biopharma
Peptinovo develops a patented nanoparticle-based drug delivery platform that targets anti-cancer therapies directly to solid tumors, enhancing the efficacy of established chemotherapies while minimizing adverse side effects. Their lead candidate, PNB-281, utilizes a proprietary carrier system to improve treatment outcomes for patients undergoing chemotherapy.
- Biotechnology
Updated 6 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Product
Problem
Many established chemotherapies, while effective against solid tumors, are limited by severe side effects that reduce patient quality of life and hinder treatment adherence. Current drug delivery methods often lack precision, leading to systemic toxicity and reduced efficacy in targeting tumor cells.
Solution
Peptinovo Biopharma is developing a targeted drug delivery platform based on its patented nanoparticle technology (PALM™) to enhance the efficacy and reduce the toxicity of existing chemotherapies. The platform utilizes a proprietary carrier system that selectively targets solid tumors, improving drug accumulation within the tumor microenvironment while minimizing exposure to healthy tissues. This approach aims to improve treatment outcomes for a broad range of solid tumors by maximizing the therapeutic index of proven chemotherapeutic agents. Peptinovo's lead candidate, PNB-281, combines the PALM™ carrier with Paclitaxel and is currently undergoing pre-IND enabling testing. Additional chemotherapy drugs have been developed using the PALM™ platform and are ready to enter pre-IND studies.
Target Audience
The primary target audience includes oncology drug developers and pharmaceutical companies seeking to improve the therapeutic profile of existing chemotherapies, as well as cancer patients who could benefit from more effective and less toxic treatment options.
Features
- PALM™ nanoparticle technology for targeted drug delivery to solid tumors
- Enhanced drug accumulation within the tumor microenvironment
- Reduced systemic toxicity compared to conventional chemotherapy
- Compatibility with a variety of proven, approved chemotherapies
- PNB-281: Lead candidate combining PALM™ with Paclitaxel
- Four additional chemotherapy drugs developed and ready for pre-IND studies